Naproxen/esomeprazole SR - Hanmi

Drug Profile

Naproxen/esomeprazole SR - Hanmi

Alternative Names: HCP 1004

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in South Korea (PO)
  • 12 Dec 2012 Phase-I clinical trials in Rheumatoid arthritis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top